DK2788372T3 - Muterede lentivirus-ENV-proteiner og anvendelse deraf som lægemidler - Google Patents

Muterede lentivirus-ENV-proteiner og anvendelse deraf som lægemidler

Info

Publication number
DK2788372T3
DK2788372T3 DK12806388.0T DK12806388T DK2788372T3 DK 2788372 T3 DK2788372 T3 DK 2788372T3 DK 12806388 T DK12806388 T DK 12806388T DK 2788372 T3 DK2788372 T3 DK 2788372T3
Authority
DK
Denmark
Prior art keywords
mutated
drugs
env proteins
lentivirus env
lentivirus
Prior art date
Application number
DK12806388.0T
Other languages
Danish (da)
English (en)
Inventor
Thierry Heidmann
Original Assignee
Viroxis S A S
Centre Nat Rech Scient
Univ Paris Sud Xi
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viroxis S A S, Centre Nat Rech Scient, Univ Paris Sud Xi, Roussy Inst Gustave filed Critical Viroxis S A S
Application granted granted Critical
Publication of DK2788372T3 publication Critical patent/DK2788372T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK12806388.0T 2011-12-07 2012-12-07 Muterede lentivirus-ENV-proteiner og anvendelse deraf som lægemidler DK2788372T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306625 2011-12-07
PCT/EP2012/074835 WO2013083799A1 (en) 2011-12-07 2012-12-07 Mutated lentiviral env proteins and their use as drugs

Publications (1)

Publication Number Publication Date
DK2788372T3 true DK2788372T3 (da) 2019-10-14

Family

ID=47435901

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12806388.0T DK2788372T3 (da) 2011-12-07 2012-12-07 Muterede lentivirus-ENV-proteiner og anvendelse deraf som lægemidler

Country Status (16)

Country Link
US (1) US9682137B2 (enExample)
EP (1) EP2788372B1 (enExample)
JP (2) JP6415324B2 (enExample)
KR (1) KR102059918B1 (enExample)
CN (1) CN104169295B (enExample)
AU (1) AU2012350258B2 (enExample)
BR (1) BR112014013704B1 (enExample)
CA (1) CA2856180C (enExample)
DK (1) DK2788372T3 (enExample)
ES (1) ES2748864T3 (enExample)
IL (1) IL232926B (enExample)
IN (1) IN2014CN04927A (enExample)
MX (1) MX350689B (enExample)
RU (1) RU2654673C2 (enExample)
WO (1) WO2013083799A1 (enExample)
ZA (1) ZA201403617B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351247B2 (en) * 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
CN117500931A (zh) * 2021-01-13 2024-02-02 维洛克塞斯 麻疹-hiv或麻疹-htlv疫苗
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
AU2005229411B2 (en) * 2004-03-30 2010-11-18 Centre National De La Recherche Scientifique Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins
EP2420248A1 (en) 2004-08-17 2012-02-22 Institut Gustave Roussy Mutated HIV NEF for modulating immunity
CA2735278A1 (en) 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
RU2426788C1 (ru) * 2010-03-01 2011-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ЦНИИЭ Роспотребнадзора) Генетические конструкции для антивич-терапии

Also Published As

Publication number Publication date
RU2654673C2 (ru) 2018-05-21
JP2018150370A (ja) 2018-09-27
AU2012350258B2 (en) 2017-03-02
ES2748864T3 (es) 2020-03-18
RU2014127521A (ru) 2016-02-10
IN2014CN04927A (enExample) 2015-09-18
EP2788372A1 (en) 2014-10-15
EP2788372B1 (en) 2019-07-10
AU2012350258A8 (en) 2014-07-17
US9682137B2 (en) 2017-06-20
IL232926A0 (en) 2014-07-31
CN104169295B (zh) 2020-07-28
BR112014013704B1 (pt) 2023-01-31
CA2856180C (en) 2022-09-06
MX2014006744A (es) 2014-12-08
JP2015505836A (ja) 2015-02-26
KR102059918B1 (ko) 2020-02-11
MX350689B (es) 2017-09-13
BR112014013704A2 (pt) 2021-02-17
AU2012350258A1 (en) 2014-06-05
CN104169295A (zh) 2014-11-26
WO2013083799A1 (en) 2013-06-13
IL232926B (en) 2019-01-31
CA2856180A1 (en) 2013-06-13
ZA201403617B (en) 2015-07-29
US20140294880A1 (en) 2014-10-02
JP6415324B2 (ja) 2018-10-31
KR20140116091A (ko) 2014-10-01

Similar Documents

Publication Publication Date Title
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
HUE054437T2 (hu) Anti-CGRP készítmények és alkalmazásuk
IL230662A0 (en) Indazoles
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
IL229143A0 (en) Titanium dioxide photocatalytic compositions and uses thereof
EP2728002A4 (en) HETERODIMIZED POLYPEPTIDE
IL238958A0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
DK3689878T3 (da) 4-imidazopyridazin-1-yl-benzamider og 4-imidazotriazin-1-yl-benzamider som btk-inhibitorer
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
HUE045348T2 (hu) Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
IL226307A0 (en) Compounds and methods for treating pain
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
DK3466969T3 (da) Lipoproteinkomplekser og fremstilling og anvendelse deraf
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
IL230838A0 (en) Pharmaceutical compositions
EP2796109A4 (en) DENTAL MEMBRANE
HUE039175T2 (hu) Ragasztóanyag és az annak alkalmazásával elõállított termék
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
HRP20181320T8 (hr) Ljudska anti-tau protutijela
BR112013014644A2 (pt) composição farmacêutica e complexo
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf